Satricabtagene autoleucel

DB18288InvestigationalCell transplant therapies

Satricabtagene autoleucel is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).

Mechanism
Curator reviewed
Also known as
satri-cel
Code names
CT041

Resolves to

Compound
UNII67B9LP62ET
Targets
P56856CLDN18

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Satricabtagene autoleucel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In